Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
4.2
Journals
Biology
Special Issues
Recent Advances in Intrahepatic Cholangiocarcinoma: Shedding Light on Clinical and...
share announcement

Recent Advances in Intrahepatic Cholangiocarcinoma: Shedding Light on Clinical and Genetic Heterogeneity

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2945

Special Issue Editors

Dr. Guglielmo Nasti

E-Mail Website
Guest Editor
Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS “G Pascale”, Naples, Italy
Interests: colorectal cancer; phase III studies; HIV-related cancers
Special Issues, Collections and Topics in MDPI journals
Dr. Alessandro Ottaiano

E-Mail Website
Guest Editor
Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via M. Semmola, 80131 Naples, Italy
Interests: abdominal cancers; colorectal cancer; immunotherapy; genomic landscape; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Cholangiocarcinoma (CCA) is a malignant neoplasm arising in the epithelium of the biliary tract. It represents the second most common primary liver cancer in the world, after hepatocellular carcinoma. CCAs are divided into intrahepatic and extrahepatic tumors according to their anatomic location. The incidence of intrahepatic CCA (iCCA) is increasing particularly in Western countries and most patients present with locally advanced or metastatic disease (involving mainly lymph nodes, peritoneum, and liver). However, in these cases, the prognosis is dismal because of low responsiveness to standard chemotherapies. Recent studies have revealed marked genetic heterogeneity underlying the development and progression of iCCA. For these reasons, iCCA is a good model for studying new putative druggable biologic pathways in cancer.

The present Special Issue is proposed to prompt scientific insights into:

  • Emerging biologic pathways involved in iCCA establishment and/or progression;
  • Prognostic and/or predictive role of specific phenotypic and/or genotypic features of iCCA;
  • Precision medicine in iCCA.

Original articles and reviews are the preferred editorial target of this Special Issue. Analyses consisting exclusively of bioinformatics or computational analyses of public databases will not be considered.

Dr. Guglielmo Nasti
Dr. Alessandro Ottaiano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intrahepatic cholangiocarcinoma
  • genetics
  • prognosis
  • precision medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 4763 KiB  
Review
Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence
by Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Francesca Grassi, Maria Chiara Brunese, Igino Simonetti, Orlando Catalano, Michela Gabelloni, Silvia Pradella, Ginevra Danti, Federica Flammia, Alessandra Borgheresi, Andrea Agostini, Federico Bruno, Pierpaolo Palumbo, Alessandro Ottaiano, Francesco Izzo, Andrea Giovagnoni, Antonio Barile, Nicoletta Gandolfo and Vittorio Mieleadd Show full author list remove Hide full author list
Biology 2023, 12(2), 213; https://doi.org/10.3390/biology12020213 - 29 Jan 2023
Viewed by 2580
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor, with a median survival of only 13 months. Surgical resection remains the only curative therapy; however, at first detection, only one-third of patients are at an early enough stage for this approach [...] Read more.
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor, with a median survival of only 13 months. Surgical resection remains the only curative therapy; however, at first detection, only one-third of patients are at an early enough stage for this approach to be effective, thus rendering early diagnosis as an efficient approach to improving survival. Therefore, the identification of higher-risk patients, whose risk is correlated with genetic and pre-cancerous conditions, and the employment of non-invasive-screening modalities would be appropriate. For several at-risk patients, such as those suffering from primary sclerosing cholangitis or fibropolycystic liver disease, the use of periodic (6–12 months) imaging of the liver by ultrasound (US), magnetic Resonance Imaging (MRI)/cholangiopancreatography (MRCP), or computed tomography (CT) in association with serum CA19-9 measurement has been proposed. For liver cirrhosis patients, it has been proposed that at-risk iCCA patients are monitored in a similar fashion to at-risk HCC patients. The possibility of using Artificial Intelligence models to evaluate higher-risk patients could favor the diagnosis of these entities, although more data are needed to support the practical utility of these applications in the field of screening. For these reasons, it would be appropriate to develop screening programs in the research protocols setting. In fact, the success of these programs reauires patient compliance and multidisciplinary cooperation. Full article
(This article belongs to the Special Issue Recent Advances in Intrahepatic Cholangiocarcinoma: Shedding Light on Clinical and Genetic Heterogeneity)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop